Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 27;3(6):481–489. doi: 10.1158/2643-3230.BCD-22-0077

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. The anti-S antibody level in CLL patients was assessed as described in the Methods. Overall response in patients (A); individual dots represent each patient. Response of individual patients before and after the third vaccination for patients on treatment (B) or no treatment (C). Patients treated with BTK inhibitors (D), anti-CD20 antibodies (E), or a combination (F) are shown. Individual lines represent each patient (B–E). Red lines indicate the median response. — The anti-S antibody level in CLL patients was assessed as described in the Methods. Overall response in patients (A); individual dots represent each patient. Response of individual patients before and after the third vaccination for patients with no treatment (B) or treatment (C). Patients treated with BTK inhibitors (D), anti-CD20 antibodies (E), or a combination (F) are shown. Individual lines represent each patient (B–E). Red lines indicate the median response.